According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on uncovering as well as creating little molecule medicine candidates to deal with cancer cells. The Business‘s products under various stages of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
Numerous other equities research experts likewise recently talked about the company. Noble Financial reissued a “purchase” ranking and also released a $11.00 rate goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” score on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day relocating typical rate of $2.90 and also a two-hundred day relocating typical price of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and also a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) incomes per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as a negative net margin of 8,294.27%. The company had profits of $0.06 million throughout the quarter, contrasted to the consensus price quote of $0.06 million. During the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will publish -1.18 EPS for the existing year.
A number of hedge funds have just recently dealt shares of ONTX. GSA Funding Partners LLP got a new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Capital Administration LP acquired a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC got a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a brand-new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Lastly, Dimensional Fund Advisors LP bought a new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional financiers have 13.36% of the business’s stock.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the recognition as well as development of oncology therapeutics. It concentrates on finding as well as developing small particle medication candidates to treat cancer. The business was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA
. Obtain a free copy of the Zacks research report on Onconova Therapeutics (ONTX).
For more information regarding research offerings from Zacks Investment Research, browse through Zacks.com.
This instantaneous news alert was produced by narrative science technology and also financial information from Market in order to provide viewers with the fastest and most accurate reporting. This tale was assessed by Market’s content team before magazine.
SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?
Prior to you think about Onconova Therapeutics, you’ll want to hear this.
Market tracks Wall Street’s premier as well as ideal performing research analysts as well as the stocks they advise to their clients each day. Market has actually recognized the five stocks that cover experts are silently murmuring to their clients to acquire currently before the broader market catches on … as well as Onconova Therapeutics had not been on the listing.
While Onconova Therapeutics presently has a “Buy” ranking amongst analysts, top-rated experts think these 5 stocks are much better acquires.